changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
The EkoSonic® Endovascular System is the first device cleared by the FDA for the treatment of Pulmonary Embolism.
In a recent study, patients receiving EKOS™ therapy had 52% shorter hospital length of stay vs patients receiving anticoagulation alone.17
The EkoSonic® Endovascular System dissolves thrombus more completely, even behind valves and IVC filters.9
EKOS™ therapy quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS).
The EkoSonic® Endovascular System safely accelerates drug penetration and clot dissolution.
Compared to traditional PAO treatment (standard CDT) EKOS therapy offers:
-Reduced treatment times
-Lower amputation rates
-Shorter hospitals stays2
24 Hour Technical Service Help 888-356-7435
(888 EKOS HELP)
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com